In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

When It Comes To Pharma R&D ROI, Mid Pharma Companies Outperform

Executive Summary

Datamonitor Healthcare's measurement of pharma R&D return on investment finds that Mid Pharma companies outperform on an ROI index. The second in a two-part series evaluating R&D productivity.

You may also be interested in...



The New World Of Pharma – Markets, Messaging And The Flash Mob

Our look back at 2016 and at prospects for the year ahead plots a rush of often conflicting head and tail winds, all requiring unrelenting focus from the C-suite on what matters to preserving pharma's vital public license to operate. Events in the sales-leading US market remain the key driver of change and a test ground for managing the competitive and reputational challenges industry faces from a more restive – and powerful – customer base.

Biopharma R&D Productivity And Growth 2016: Innovation Performance Improves

Catenion updates its annual list of the year's top pharma R&D performers, based on R&D productivity and growth. This year Regeneron shoots to the top and Gilead drops to third place.

Pharma R&D Efficiency: Mid-Sized Companies Excel

Datamonitor Healthcare's recent review of R&D efficiency using new product launch success rates as a proxy shows that Mid Pharma companies outperform Big Pharma and Japan Pharma firms, thanks to multiple blockbuster drugs. The first in a two-part series evaluating R&D productivity.

Topics

Related Companies

UsernamePublicRestriction

Register

IV004934

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel